Table 2.
Antimicrobial susceptibility of Thai Streptococcus suis isolated from human patients (27 strains), diseased pigs (46 strains), and asymptomatic pigs (189 strains)
| Antibiotic drugs | Human patients 27 strains |
Diseased pigs 46 strains |
Asymptomatic pigs 189 strains |
P-value | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| S | I | R | S | I | R | S | I | R | ||
| AMP | 27 (100%) | 0 (0%) | 0 (0%) | 40 (86.9%) | 2 (4.4%) | 4 (8.7%) | 125 (66.1%) | 23 (12.2%) | 41 (21.7%) | 0.001* |
| CFL | 27 (100%) | 0 (0%) | 0 (0%) | 34 (73.9%) | 1 (2.2%) | 11 (23.9%) | 104 (55.0%) | 4 (2.1%) | 81 (42.9%) | < 0.001* |
| CTX | 27 (100%) | 0 (0%) | 0 (0%) | 38 (82.6%) | 2 (4.4%) | 6 (13.0%) | 179 (94.7%) | 2 (1.1%) | 8 (4.2%) | 0.029* |
| CTF | 27 (100%) | 0 (0%) | 0 (0%) | 39 (84.8%) | 3 (6.5%) | 4 (8.7%) | 182 (96.3%) | 2 (1.1%) | 5 (2.6%) | 0.018* |
| PEN | 27 (100%) | 0 (0%) | 0 (0%) | 33 (71.7%) | 8 (17.4%) | 5 (10.9%) | 59 (31.2%) | 79 (41.8%) | 51 (27.0%) | < 0.001* |
| VAN | 27 (100%) | 0 (0%) | 0 (0%) | 42 (91.3%) | 1 (2.2%) | 3 (6.5%) | 184 (97.4%) | 4 (2.1%) | 1 (0.5%) | 0.042* |
| AZM | 5 (18.5%) | 0 (0%) | 22 (81.5%) | 9 (19.6%) | 0 (0%) | 37 (80.4%) | 26 (13.8%) | 4 (2.1%) | 159 (84.1%) | 0.619 |
| CHL | 24 (88.9%) | 3 (11.1%) | 0 (0%) | 37 (80.4%) | 4 (8.7%) | 5 (10.9%) | 168 (88.9%) | 10 (5.3%) | 11 (5.8%) | 0.254 |
| CLI | 5 (18.5%) | 0 (0%) | 22 (81.5%) | 5 (10.9%) | 0 (0%) | 41 (89.1%) | 7 (3.7%) | 0 (0%) | 182 (96.3%) | 0.006* |
| DOX | 0 (0%) | 0 (0%) | 27 (100%) | 2 (4.4%) | 2 (4.4%) | 42 (91.3%) | 22 (11.6%) | 3 (1.6%) | 164 (86.8%) | 0.114 |
| ERY | 4 (14.8%) | 4 (14.8%) | 19 (70.4%) | 9 (19.6%) | 1 (2.2%) | 36 (78.2%) | 30 (15.9%) | 2 (1.1%) | 157 (83.0%) | 0.001* |
| FFC | 26 (96.3%) | 1 (3.7%) | 0 (0%) | 36 (78.2%) | 0 (0%) | 10 (21.8%) | 180 (95.3%) | 1 (0.5%) | 8 (4.2%) | < 0.001* |
| GEN | 22 (81.5%) | 3 (11.1%) | 2 (7.4%) | 11 (23.9%) | 9 (19.6%) | 26 (56.5%) | 67 (35.5%) | 49 (25.9%) | 73 (38.6%) | < 0.001* |
| TET | 0 (0%) | 0 (0%) | 27 (100%) | 3 (6.5%) | 2 (4.4%) | 41 (89.1%) | 10 (5.3%) | 5 (2.6%) | 174 (92.1%) | 0.552 |
| TIA | 0 (0%) | 23 (85.2%) | 4 (14.8%) | 4 (8.7%) | 5 (10.9%) | 37 (80.4%) | 2 (1.1%) | 17 (9.0%) | 170 (89.9%) | < 0.001* |
| CIP | 20 (74.1%) | 5 (18.5%) | 2 (7.4%) | 32 (69.5%) | 5 (10.9%) | 9 (19.6%) | 103 (54.5%) | 26 (13.8%) | 60 (31.7%) | 0.048* |
| ENR | 15 (55.6%) | 12 (44.4%) | 0 (0%) | 23 (50.0%) | 15 (32.6%) | 8 (17.4%) | 105 (55.6%) | 29 (15.3%) | 55 (29.1%) | < 0.001* |
| NOR | 5 (18.5%) | 19 (70.4%) | 3 (11.1%) | 13 (28.3%) | 13 (28.3%) | 20 (43.4%) | 47 (24.9%) | 41 (21.7%) | 101 (53.4%) | < 0.001* |
| LEV | 27 (100%) | 0 (0%) | 0 (0%) | 41 (89.1%) | 1 (2.2%) | 4 (8.7%) | 134 (70.9%) | 5 (2.6%) | 50 (26.5%) | 0.003* |
| SXT | 27 (100%) | 0 (0%) | 0 (0%) | 18 (39.1%) | 6 (13.0%) | 22 (47.9%) | 50 (26.5%) | 4 (2.1%) | 135 (71.4%) | < 0.001* |
AMP ampicillin, AZM azithromycin, CTX cefotaxime, CTF ceftiofur, CFL cephalexin, CHL chloramphenicol, CIP ciprofloxacin, CLI clindamycin, DOX doxycycline, ENR enrofloxacin, ERY erythromycin, FFC florfenicol, GEN gentamiycin, LEV levofloxacin, NOR norfloxacin, PEN penicillin G, SXT sulfamethoxazole/trimethoprim, TET tetracyclin, TIA tiamulin, VAN: vancomycin. S susceptible; I intermediate; R resistant. The asterisk indicates statistical significance with P-value < 0.05